Johnson & Johnson

(

JNJ

) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day down 1.4%. By the end of trading, Johnson & Johnson fell 38 cents (-0.6%) to $62.21 on average volume. Throughout the day, 8.5 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 11.2 million shares. The stock ranged in price between $62-$62.40 after having opened the day at $62.35 as compared to the previous trading day's close of $62.59. Other company's within the Health Care sector that declined today were:

Synergetics USA

(

SURG

), down 28.1%,

iBio

(

IBIO

), down 13.2%,

Rosetta Genomics

(

ROSG

), down 11.8%, and

Complete Genomics

(

GNOM

), down 11.5%.

Johnson & Johnson engages in the research, development, manufacture, and sale of various products in the health care field worldwide. Johnson & Johnson has a market cap of $171.68 billion and is part of the

drugs

industry. The company has a P/E ratio of 17.1, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 4.6% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Johnson & Johnson a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

null